Dashboard
Manage Tickers

ASND


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wells-fargo-maintains-overweight-on-ascendis-pharma-raises-price-target-to-289
Wells Fargo Maintains Overweight on Ascend...
09/17/2024 15:42:18

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from...

citigroup-maintains-buy-on-ascendis-pharma-raises-price-target-to-207
Citigroup Maintains Buy on Ascendis Pharma...
09/17/2024 15:21:30

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $178 to...

evercore-isi-group-maintains-outperform-on-ascendis-pharma-raises-price-target-to-205
Evercore ISI Group Maintains Outperform on...
09/17/2024 13:57:56

Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price targ...

oppenheimer-reiterates-outperform-on-ascendis-pharma-raises-price-target-to-190
Oppenheimer Reiterates Outperform on Ascen...
09/17/2024 13:49:54

Oppenheimer analyst Leland Gershell reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target f...

goldman-sachs-maintains-buy-on-ascendis-pharma-raises-price-target-to-200
Goldman Sachs Maintains Buy on Ascendis Ph...
09/17/2024 13:26:25

Goldman Sachs analyst Paul Choi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $180 to ...

despite-being-first-mover-biomarins-voxzogo-for-dwarfism-to-face-pressure-from-ascendis-candidate-in-near-term
Despite Being First Mover, BioMarin's Voxz...
09/16/2024 19:12:28

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by l...

crude-oil-surges-over-1-instil-bio-shares-plunge
Crude Oil Surges Over 1%; Instil Bio Share...
09/16/2024 16:31:33

ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year
Ascendis Pharma's Rare Dwarfism Candidate ...
09/16/2024 16:18:34

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia.

alcoa-lattice-semiconductor-stratasys-and-other-big-stocks-moving-higher-on-monday
Alcoa, Lattice Semiconductor, Stratasys An...
09/16/2024 14:03:58

cantor-fitzgerald-reiterates-overweight-on-ascendis-pharma-maintains-170-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 12:22:09

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $170 price target.

ascendis-pharma-announced-topline-data-from-the-pivotal-approach-trial-of-transcon-cnp-navepegritide-which-included-84-children-with-achondroplasia-showing-once-weekly-transcon-cnp-demonstrated-annualized-growth-velocity-superior-to-placebo
Ascendis Pharma Announced Topline Data Fro...
09/16/2024 11:08:12

ascendis-to-present-first-results-from-platinum-resistant-ovarian-cancer-cohort-of-the-phase-12-il-believe-trial-at-esmo-2024
Ascendis To Present First Results From Pla...
09/13/2024 12:31:42

Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 β...

ascendis-pharma-says-fda-granted-orphan-drug-exclusivity-to-yorvipath-for-treatment-of-hypoparathyroidism-in-adults
Ascendis Pharma Says FDA Granted Orphan Dr...
09/11/2024 21:39:15

YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once daily, designed to provide continuous exposure to...

cantor-fitzgerald-reiterates-overweight-on-ascendis-pharma-maintains-170-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:13:56

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $170 price target.

ascendis-pharma-shares-are-trading-higher-after-oppenheimer-upgraded-the-stock-from-perform-to-outperform-and-announced-a-180-price-target
Ascendis Pharma shares are trading higher ...
09/05/2024 13:55:41

oppenheimer-upgrades-ascendis-pharma-to-outperform-announces-180-price-target
Oppenheimer Upgrades Ascendis Pharma to Ou...
09/05/2024 12:04:29

Oppenheimer analyst Leland Gershell upgrades Ascendis Pharma (NASDAQ:ASND) from Perform to Outperform and announces $180 pri...

citigroup-maintains-buy-on-ascendis-pharma-lowers-price-target-to-178
Citigroup Maintains Buy on Ascendis Pharma...
09/05/2024 00:09:11

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $193 to...

jp-morgan-maintains-overweight-on-ascendis-pharma-lowers-price-target-to-165
JP Morgan Maintains Overweight on Ascendis...
09/04/2024 22:23:19

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $17...

ascendis-pharma-faces-challenges-with-skytrofa-and-yorvipath-pricing-analysts-weigh-in
Ascendis Pharma Faces Challenges With Skyt...
09/04/2024 21:02:35

Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included...

td-cowen-maintains-buy-on-ascendis-pharma-lowers-price-target-to-157
TD Cowen Maintains Buy on Ascendis Pharma,...
09/04/2024 17:18:01

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $175 to $157.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION